KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) In Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3Ko Inhibitor Therapy

¹University of Pennsylvania, Philadelphia, PA; ²New York-Presbyterian Columbia University Medical Ctr, New York, NY; ³Sarah Cannon Research Institute, University of Rochester, Rochester, NY; ³Sarah Cannon Research Institute, University of Rochester, Rochester, NY; ³Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University of Rochester, NY; ⁴Tennessee Oncology/Sarah Cannon Research Institute, University Institute, Institute, University Institute, Institute, University Institute, Ins ⁷Swedish Cancer Institute, Seattle, WA; ⁸Northwell Health/CLL Research and Treatment Program, New Hyde Park, NY; ⁹Dartmouth-Hitchcock Medical Ctr, Lebanon, NH; ¹⁰Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL; ¹¹Penn State Health, Hershey, PA; ¹²John Theurer Cancer Center, Hackensack, NJ; ¹³Duke University Medical Ctr, Lebanon, NH; ¹⁰Florida Cancer Specialists/Sarah Cannon Research and Treatment Program, New Hyde Park, NY; ⁹Dartmouth-Hitchcock Medical Ctr, Lebanon, NH; ¹⁰Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL; ¹¹Penn State Health, Hershey, PA; ¹²John Theurer Cancer Center, Hackensack, NJ; ¹³Duke University Medical Ctr, Lebanon, NH; ¹⁰Florida Cancer Specialists/Sarah Canc


Background / Rationale

- *Kinase inhibitor (KI) therapies such as ibrutinib are Umbralisib generally well tolerated, although intolerance is the most common reason for discontinuation in practice (~50% of discontinuations, Mato et al, Blood 2016). Data shows that KI-intolerant patients (pts) can be successfully treated with an alternate KI (Fig 1). Additionally, it has been reported that KI interruptions \geq 8 days can shorten Overall Survival (Barr, et al Blood 2017). Therefore, pts who discontinue a KI due to intolerance represent an unmet need.
- Fortunately, data suggest that alternate KIs can have non-overlapping toxicity profiles.

Figure 1: PFS on Alternate KI (Mato et al, Blood 2016)

PFS by Discontinuation Reason (treated with alternate KI) PFS From Start of Alternate KI Median PFS not reached Median PFS 7 months Months CLL Progression KI Intolerance

- observed to date;
- A prolonged half-life that enables once-daily dosing;
- \clubsuit High selectivity to the δ isoform of PI3K; and
- \Rightarrow Also targets casein kinase-1 epsilon (CK-1 ϵ), a protein which may inhibit regulatory T-cell function



Study Design/Methods

- Phase II, multicenter, single-arm trial of umbralisib monotherapy in CLL pts who are intolerant to prior KI therapy (NCT02742090).
- Enrollment: Up to 50 patients who have discontinued prior therapy with a BTK or PI3K-delta inhibitor due to intolerance.

Prior KI Therapy: BTK or PI3Kδ

Intolerance is defined as unacceptable toxicity where, in the opinion of the investigator, treatment should be discontinued in spite of optimal supportive care as a result of one of the following:

- 3 2 or more Grade ≥ 2 non-hematological toxicities;
- 3 1 or more Grade ≥ 3 non-hematological toxicity; 1 or more Grade 3 neutropenia with infection or fever; or
- Grade 4 heme tox which persists to the point that the investigator chose to stop therapy due to toxicity NOT progression.

Toxicity must have resolved to ≤ Grade 1 prior to umbralisib dosing



Study Objectives Primary Objective

To determine the PFS of umbralisib in CLL pts intolerant to prior BTK / PI3K δ inhibitors **Secondary Objectives**

- ✤ To evaluate the ORR and duration of response (DOR) of umbralisib.
- To evaluate Time to Treatment Failure with umbralisib as compared to prior KI therapy. To evaluate the safety profile of umbralisib as compared to the prior KI therapy.

Key Eligibility Criteria

- CLL pts whose prior therapy with a BTK inhibitor (ibrutinib, acalabrutinib) or a PI3K δ inhibitor (idelalisib, duvelisib) was D/C due to intolerance within 12 mos of C1/D1.
- discontinuation w/o disease progression.
- Meets KI Intolerance as defined to the left. Off prior KI for at least 14 days following • ANC > 1,000/ μ L, platelet count > 30,000/ μ L.

Anthony R. Mato, MD¹, Nicole Lamanna, MD², Suman Kambhampati, MD³, Ian W. Flinn, MD, PhD⁴, Jeffrey J. Pu, MD, PhD¹, Alan Skarbnik, MD¹², Colleen Dorsey, BSN, RN¹, Elizabeth T Chatburn, BS¹, Hanna Weissbrot, BS², Jakub Svoboda, MD¹, Stephen J. Schuster, MD¹, Patricia Tsao, MD, PhD¹, Andrea Sitlinger, MD¹³, Chaitra S. Ujjani, MD², Dana Paskalis¹⁴, Peter Sportelli¹⁴, Hari P. Miskin, MS¹⁴, Michael S. Weiss¹⁴ and Danielle M. Brander, MD¹³

Results

\bullet Umbralisib (TGR-1202) is a next generation PI3K δ inhibitor, with a unique structure and activity profile distinct from other PI3K δ inhibitors in development, including:

 \Rightarrow A differentiated safety profile from other PI3K δ inhibitors, notably with respect to hepatic toxicity and colitis

Comparison of Structure and Lipid Kinase Inhibition Profile

Demographics
Evaluable for Safety, n
Evaluable for PFS ⁺ , n
Median Age, years (range)
Male/Female
ECOG, 0/1/2
Prior Therapy Regimens, median (range)
17p del, n (%)
11q del, n (%)
IGHV Unmutated, n (%)
Bulky Disease, n (%)
Prior BTK, n
Prior PI3K, n
Median Time on Prior TKI, mos (range)

Median Time from D/C of Prior TKI to Enrollme

Requiring treatment within 6 mos of Prior TKI,

[†]1 patient with confirmed Richter's Transformation at enrollment (not eligible); removed from PFS analysis

Adverse Event Leading to Prior BTK/PI3K Discontinuation

Intolerant AE on Prior TKI	Grade 2	Grade 3	Grade 4	Total # of Events
Arthralgia	3	4	-	7
Rash	3	4	-	7
A-Fib	3	2	1	6
Diarrhea	2	2	-	4
Anorexia/Weight Loss	3	-	-	3
Bleeding	1	2	-	3
Fatigue	2	1	-	3
Bruising	2	-	-	2
CHF	-	1	1	2
Colitis*	-	2	-	2
Dizziness	1	-	-	1
Edema	1	-	-	1
Hypertension	1	-	-	1
Pericardial Effusion	-	-	1	1
Mental status change	-	1	-	1
Respiratory Failure	-	-	1	1
Transaminitis*	1	-	-	1

* All 3 events were idelalisib intolerant patients (2 pts colitis and 1 transaminitis)


	33
	32
	67 (53 – 96)
	18 / 15
	13 / 18 / 2
	2 (1 – 7)
	5 (15%)
	7 (21%)
	16 (48%)
	13 (39%)
	30
	3
	11 (1 – 38)
nt, mos (range)	3 (1 – 15)
n (%)	25 (76%)

Safety

All Grade / All Causality A	E's >15% o	r Grade	3/4 > 5%	(N = 33)			
Adverse Event	All Gra	ades	Grade 3/4				
	N	%	Ν	%			
Nausea	16	48%	-	-			
Diarrhea	14	42%	2	6%			
Thrombocytopenia	8	24%	2	6%			
Insomnia	8	24%	-	-	•		
Neutropenia	7	21%	6	18%			
Fatigue	7	21%	-	-			
Peripheral Edema	7	21%	-	-			
Cough	6	18%	-	-			
Dizziness	6	18%	-	-			
Febrile neutropenia	3	9%	3	9%			
Hypophosphatemia	2	6%	2	6%			
Mean time on study = 6 mos (range 1 – 13 mos)							

 \sim iviean time on study = 6 mos (range 1 – 13 mos)

Efficacy



Conclusions

- Enrollment continues with up to 50 patients expected in this TKI intolerant patient population.

AST/ALT Increase = 3% (One Grade 1 event)

- Of the 14 events of diarrhea, 8 were Grade 1, 4 were Grade 2, and 2 were Grade 3
- ✤ 1 case of colitis reported after 6 weeks on treatment recovered after 2 week hold, and did not recur on rechallenge at 600 mg daily – patient remains in Partial Response 10+ months on study
- 2 (6%) pts discontinued treatment due to an umbralisib AE (pancreatitis and rash); neither were recurrent AE's that led to prior KI intolerance
- 2 pts had recurrence of an AE that led to intolerance on their prior TKI, however both recurrences were of lesser severity, and neither led to discontinuation or dosemodification of umbralisib
- ✤ 3 (9%) pts had dose reductions (headache, neutropenia, colitis)
- 1 event of pneumonia was reported and deemed not related to umbralisib

Umbralisib as a single agent demonstrates a favorable safety profile in patients intolerant to prior ibrutinib or idelalisib, with only 2 patients (6%) discontinuing due to an AE, none of which was a recurrent AE from prior TKI therapy.

In this high-risk group of patients, of which 76% required treatment within 6 months of discontinuation from a prior BTK or PI3K inhibitor, 94% remain progression-free with a median time on study of 6 mos.